Is NSC 683769 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use NSC 683769? Is NSC 683769 safe for nursing mother and child? Does NSC 683769 extracts into breast milk? Does NSC 683769 has any long term or short term side effects on infants? Can NSC 683769 influence milk supply or can NSC 683769 decrease milk supply in lactating mothers?

Biliary salt that appears in low amount in the serum because it is absorbed to the portal circulation and completely excreted into biliary duct. Excreted into breast milk in non-significant amount with no side-effects being observed among infants of treated mothers. Medication that has been used for treatment of newborns and older infants.

Because of the low levels of NSC 683769 (ursodeoxycholic acid) in breastmilk, amounts ingested by the infant are small and are not expected to cause any adverse effects in breastfed infants. No special precautions are required.

One breastfed (extent not stated) infant developed normally over the first 6 months of life during maternal NSC 683769 therapy of 750 to 1000 mg daily.[1] Seven women who were taking NSC 683769 14 mg/kg daily near term and postpartum. They reported no adverse reactions in their breastfed infants during the early postpartum period.[2] A mother receiving oral NSC 683769 250 mg 3 times daily for primary biliary cirrhosis reportedly breastfed her infant normally, although the extent and duration of breastfeeding was not stated.[4] A woman with primary biliary cirrhosis developed severe pruritus and elevated serum bile acids 3 weeks postpartum. NSC 683769 was started at a dose of 500 mg (7.5 mg/kg) daily, increasing to 1500 mg (25 mg/kg) daily over the next 8 weeks. Psychomotor development of her breastfed (extent not stated) infant was normal, and no apparent side effects were observed in the infant.[3] A woman was breastfeeding her 8-day-old preterm infant 10 times daily for about 15 minutes each time. The infant was born by cesarean section at 34 weeks of gestation with a weight of 3600 grams,. She was diagnosed with cholestasis, type 1 diabetes, and hypothyroidism. She was treated with NSC 683769 500 mg daily, insulin levemir and aspart, and levothyroxine. She was also taking cefuroxime, flurbiprofen, a combination of acetaminophen, propyphenazone, and caffeine. The mother took the NSC 683769 for a total of 12 days, cefuroxime and the analgesic combination for 10 days and flurbiprofen for 15 days. No adverse effects were noticed during the period of NSC 683769 treatment.[5]